Scroll for more

What if a scientist could remember every paper they have ever read and read every paper that had ever been written in medicine, physics or material sciences …

...AND possessed the expertise needed to truly understand all that information in the right contexts

…AND could draw eureka moments from that knowledge

Imagine the sheer scale and speed of the discoveries that could be made.

BenevolentAI does this every day

Our story

BenevolentAI was founded in 2013 by Ken Mulvany following the sale of Proximagen, a successful biotech business that Ken founded.  The experience of running a biotech, a company in an industry entirely reliant on scientific breakthroughs, highlighted the challenges of innovating using a process of scientific discovery that had not largely changed for 50 years. 

The sheer volume of information available means no scientist, or group of scientists, can possibly assimilate, recall and accurately process all the known facts.  Consequently, only a fraction of relevant knowledge guides hypotheses and a fundamental bottleneck exists – a rapidly accelerating mismatch between information and humanity’s ability to process it. 

BenevolentAI was established to build and apply artificial intelligence to humankind’s new natural resource – data, and by doing so unlock science’s ‘hidden knowledge’ and turn highly fragmented unstructured and structured information into new insight and usable knowledge.

Headquartered in London’s Knowledge Quarter, BenevolentAI is focussed on forging a powerful union between humans, technology and science using AI.  The Company’s purpose is to dramatically accelerate innovation in industries that rely on science-based ideas, inventions and products and overcome some of the world’s greatest scientific challenges.

BenevolentAI’s initial scientific focus has been in human health, specifically rare disease groups in often overlooked areas.  In human health, BenevolentAI has harnessed its technology to make major breakthroughs and accelerate drug development..  The Company has entered into significant license agreements with some of the world’s largest pharmaceutical companies and is beginning its first Phase IIb clinical study in 2017.

BenevolentAI currently operates two distinct business units; ‘BenevolentBio’ which applies BenevolentAI’s technology in human health and the exploration of further bioscience applications, and, ‘BenevolentTech’ which refines and develops the company’s technology and replicates its initial success across wider applications and industries.


BenevolentBio is focussed on applying the Company’s technology in the bioscience industries.  The initial focus has been on human health – generating new ideas that have the potential to improve the lives of millions and deliver better medicines to patients faster in currently overlooked areas such as orphan diseases and rare cancers.

We apply our AI to radically improve the efficiency of drug development, produce better target selection, optimise compounds and draw previously impossible insights from hundreds of millions of associations between biologically meaningful entities and unstructured text.

Our world-class scientific team, enabled by our proprietary technology has made rapid progress.  We have developed a significant pipeline of drug candidate programmes ranging from early-stage discovery assets to Phase IIb clinical development assets and are working with major pharmaceutical groups to licence compounds and develop drugs.  We also work closely with charities and other funders, especially in rare disease areas.

As we demonstrate the success of our technology and progress our pipeline of new therapeutic agents for human diseases, we will extend our activity into other bioscience areas such as veterinary medicine and nutraceuticals.


BenevolentTech is developing an advanced artificial intelligence platform that helps scientists make new discoveries and redefines how scientists gain access to, and use, all the data available to them to drive innovation.  The technology is built upon a deep judgement system that learns and reasons from the interaction between human judgement and data.

Simply put, the technology probes ‘hidden’ scientific knowledge and and deduces what ‘should’ be known based on what ‘is’ already known.  The platform, and its associated unique systems and designed AI tools, generates usable knowledge from vast volumes of unstructured information in scientific papers, patents, clinical trial information and from a large number of structured data sets. 

The technology understands information by employing an array of proprietary deep learning linguistic models and algorithms to analyse and understand context; then reasons, learns, explores, creates and translates what it has learnt to produce unique hypotheses.  The platform is unlike a typical computing system, in that it is not programmed, rather it continuously learns on its own from interactions with experts.

BenevolentAI believes that the way it brings science and computer technology together is unique.  BenevolentAI combines the power of machine brains with expert human brains to understand the wealth of big, complex and ever-changing data.  The technological goal is to augment human judgment - to assist the creative process that characterises the very best scientist. 

The technology enables previously impossible scientific discoveries by finding connections that would otherwise have been missed.  The first use case has been applying our software to automate the extraction of biological knowledge, undertake predictive and generative biochemistry, and advance better therapeutic molecules thus enabling our drug discovery scientists to develop new medicines more efficiently.

our neighbourhood

BenevolentAI is headquartered in the ‘Knowledge Quarter’ tech cluster in Kings Cross, London - a neighbourhood of highly respected academic institutions and technology innovators including Google, Facebook, The Alan Turing Institute, The Francis Crick Institute, Wellcome Trust, Digital Catapult and University College London. We also have offices in Belgium and New York.

72,000 people

73 organisations

1 mile radius